Payment overview · 2025
General Payments
$457.10
19 reported records · 10 companies
Healthcare provider profile · identity verified
Leo K Edwards, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAN ANTONIO, TX · NPI 1750313441
Verified facts
What the public records show
CMS Open Payments records show Leo K Edwards, M.D. received $457.10 in general payments during 2025 across 19 reported records.
AstraZeneca Pharmaceuticals LP accounted for 43.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $196.84 | 43.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.10 | 15.3% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $46.08 | 10.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.28 | 7.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.64 | 6.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.17 | 5.3% | 1 | 2025 |
| Cumberland Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.60 | 3.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.97 | 3.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.50 | 3.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.92 | 2.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $457.10 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $164.28 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $163.93 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $131.37 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $70.10 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $70.10 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $46.08 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $34.28 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.64 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| KRISTALOSE Normalized: kristalose |
Drug | Cumberland Pharmaceuticals, Inc. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.92 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 186 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 19 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
186 | 47 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
124 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
93 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
113 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 934 | 169 |
| Simvastatin | Simvastatin | 847 | 205 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 768 | 153 |
| Pantoprazole Sodium | Pantoprazole Sodium | 741 | 159 |
| Losartan Potassium | Losartan Potassium | 737 | 171 |
| Amlodipine Besylate | Amlodipine Besylate | 725 | 180 |
| Lisinopril | Lisinopril | 681 | 159 |
| Furosemide | Furosemide | 567 | 135 |
| Metformin Hcl | Metformin Hcl | 553 | 128 |
| Tramadol Hcl | Tramadol Hcl | 546 | 120 |
| Nifedipine Er | Nifedipine | 523 | 120 |
| Alprazolam | Alprazolam | 499 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 487 | 116 |
| Hydrochlorothiazide | Hydrochlorothiazide | 479 | 122 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 463 | 119 |
| Montelukast Sodium | Montelukast Sodium | 455 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 445 | 130 |
| Naproxen | Naproxen | 434 | 98 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 432 | 101 |
| Ibuprofen | Ibuprofen | 414 | 85 |
| Carvedilol | Carvedilol | 359 | 87 |
| Omeprazole | Omeprazole | 350 | 76 |
| Meloxicam | Meloxicam | 318 | 73 |
| Sertraline Hcl | Sertraline Hcl | 297 | 53 |
| Amoxicillin | Amoxicillin | 295 | 172 |
| Ozempic | Semaglutide | 293 | 52 |
| Pioglitazone Hcl | Pioglitazone Hcl | 248 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 244 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 237 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 224 | 52 |
| Pregabalin | Pregabalin | 210 | 53 |
| Tizanidine Hcl | Tizanidine Hcl | 208 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 187 | 28 |
| Linzess | Linaclotide | 186 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 179 | 38 |
| Alendronate Sodium | Alendronate Sodium | 171 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 169 | 39 |
| Trazodone Hcl | Trazodone Hcl | 164 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 162 | 37 |
| Temazepam | Temazepam | 160 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 21 |
| Levetiracetam | Levetiracetam | 149 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 139 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 134 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 31 |
| Symbicort | Budesonide/Formoterol Fumarate | 124 | 35 |
| Allopurinol | Allopurinol | 123 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 120 | 34 |
| Mounjaro | Tirzepatide | 120 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 118 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 118 | 33 |
| Azithromycin | Azithromycin | 117 | 74 |
| Clonidine Hcl | Clonidine Hcl | 117 | 24 |
| Meclizine Hcl | Meclizine Hcl | 117 | 29 |
| Eliquis | Apixaban | 113 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 111 | 82 |
| Metoclopramide Hcl | Metoclopramide Hcl | 97 | 19 |
| Potassium Chloride | Potassium Chloride | 96 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 95 | 13 |
| Spironolactone | Spironolactone | 95 | 21 |
| Januvia | Sitagliptin Phosphate | 93 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 93 | 22 |
| Clotrimazole | Clotrimazole | 90 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 23 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 85 | 32 |
| Ventolin Hfa | Albuterol Sulfate | 82 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 28 |
| Lorazepam | Lorazepam | 80 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 72 | 11 |
| Bumetanide | Bumetanide | 71 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 11 |
| Methylprednisolone | Methylprednisolone | 64 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 14 |
| Donepezil Hcl | Donepezil Hcl | 62 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 62 | suppressed |
| Aripiprazole | Aripiprazole | 59 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 58 | 15 |
| Buspirone Hcl | Buspirone Hcl | 57 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 56 | 30 |
| Prednisone | Prednisone | 55 | 28 |
| Celecoxib | Celecoxib | 53 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 52 | 16 |
| Jardiance | Empagliflozin | 52 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 18 |
| Irbesartan | Irbesartan | 50 | 13 |
| Trulicity | Dulaglutide | 49 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | suppressed |
| Sucralfate | Sucralfate | 48 | 15 |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 47 | 27 |
| Famotidine | Famotidine | 47 | 13 |
| Indomethacin | Indomethacin | 47 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 43 | 11 |
| Chlorthalidone | Chlorthalidone | 41 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Gemtesa | Vibegron | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Glyburide | Glyburide | 38 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Risperidone | Risperidone | 38 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 36 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 13 |
| Fluconazole | Fluconazole | 33 | 21 |
| Glipizide | Glipizide | 33 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | 11 |
| Topiramate | Topiramate | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Jantoven | Warfarin Sodium | 20 | suppressed |
| Sulfasalazine | Sulfasalazine | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 18 |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Safetyglide Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Sure Comfort | Pen Needle, Diabetic | 12 | suppressed |
| Tacrolimus | Tacrolimus | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $457.10 · 19 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, FARXIGA, KEVEYIS, KRISTALOSE, LINZESS, OTEZLA, PAXLOVID, REPATHA, SHINGRIX, VOQUEZNA, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error